Bariatric surgery decline tied to rise in GLP-1 drugs to treat obesity

A new study by researchers at Brigham and Women’s Hospital in collaboration with researchers at Harvard T.H. Chan School of Public Health and the Brown School of Public Health, examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than doubled from 2022 to 2023.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup